Publications

Search
Clinical
ASCO GI
January 9, 2026
A Phase 1, First-in-Human, Multicenter Study of ZW251, a Novel Glypican-3 (GPC3)-Targeted Antibody-Drug Conjugate (ADC), in Participants With Hepatocellular Carcinoma (HCC)
Chandana et al.
Clinical
ASCO GI
January 8, 2026
Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01
Elimova et al.
Preclinical
World ADC San Diego
November 5, 2025
ZW327 – A Topoisomerase-1 inhibitor ADC Designed to Target Ly6E-Expressing Tumors
Stuart Barnscher
Preclinical
SITC
November 8, 2025
TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation and transferability to diverse targeting strategies
Verstrate et al.
Preclinical
November 7, 2025
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
Preclinical
SITC
November 7, 2025
High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Church et al.
Clinical, ZW191
AACR-EORTC-NCI
October 23, 2025
Preliminary Results From a Phase 1 First-in-Human Multicenter Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors
LoRusso et al.
Preclinical, ZW1528
ERS
September 30, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Hardman et al.
Preclinical, ZW1528
World Bispecific Summit
September 10 - September 10, 2025
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Alexey Berezhnoy, PhD
Preclinical
Immuno-Oncology Summit
August 11, 2025
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
Preclinical
T cell Engager Summit
June 26, 2025
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
Clinical, ZW191
ESMO Gynaecological Cancers Congress
June 19, 2025
Design of a First-in-Human Multicentre Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate Utilising a Novel TOPOIi Payload, in Participants With Advanced Solid Tumours: ZWI-ZW191-101
Sommerhalder et al.